1. Home
  2. TPST

TPST

Tempest Therapeutics Inc.

Logo Tempest Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 10:39am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Founded: 2011 Country:
United States
United States
Employees: N/A City: BRISBANE
Market Cap: 79.7M IPO Year: N/A
Target Price: $22.25 AVG Volume (30 days): 1.0M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.91 EPS Growth: N/A
52 Week Low/High: $0.17 - $9.77 Next Earning Date: 05-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: